Amylyx Drug Patent Portfolio
Amylyx owns 1 orange book drug protected by 5 US patents Given below is the list of Amylyx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11583542 | Compositions of bile acids and phenylbutyrate compounds | 27 Jul, 2040 | Active |
| US10251896 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
| US10857162 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
| US11071742 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
| US9872865 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
Latest Legal Activities on Amylyx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amylyx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9872865 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10857162 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10251896 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US11071742 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US10251896 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US9872865 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US11071742 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US10857162 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10857162 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US11071742 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10251896 |
| Letter re PTE application to FDA or Dept of Agriculture | 30 Sep, 2023 | US9872865 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US10251896 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US9872865 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US10857162 |
Amylyx's Family Patents
Amylyx drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 25.9% of its total global patent coverage. Click
below to unlock the full patent family tree.
Amylyx Drug List
Given below is the complete list of Amylyx's drugs and the patents protecting them.
1. Relyvrio
Relyvrio is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11583542 | Compositions of bile acids and phenylbutyrate compounds |
27 Jul, 2040
(15 years from now)
| Active |
| US10251896 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(8 years from now)
| Active |
| US10857162 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(8 years from now)
| Active |
| US11071742 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(8 years from now)
| Active |
| US9872865 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relyvrio's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List